Efficacy and durability of radiofrequency ablation for barrett's esophagus

Systematic review and meta-analysis

Eric Orman, Nan Li, Nicholas J. Shaheen

Research output: Contribution to journalReview article

143 Citations (Scopus)

Abstract

Background & Aims: In patients with Barrett's esophagus (BE), radiofrequency ablation (RFA) safely and effectively eradicates dysplasia and intestinal metaplasia. We aimed to determine the efficacy and durability of RFA for patients with dysplastic and nondysplastic BE. Methods: We performed a systematic review and meta-analysis of studies identified in PubMed and EMBASE that reported the proportion of patients treated with RFA who had complete eradication of dysplasia (CE-D) and intestinal metaplasia (CE-IM), and the proportion of patients with recurrent IM after successful treatment. Pooled estimates of CE-D, CE-IM, IM recurrence, and adverse events were calculated. Results: We identified 18 studies of 3802 patients reporting efficacy and 6 studies of 540 patients reporting durability. Ten were prospective cohort studies, 9 were retrospective cohort studies, and 1 was a randomized trial. CE-IM was achieved in 78% of patients (95% confidence interval [CI], 70%-86%) and CE-D was achieved in 91% (95% CI, 87%-95%). After eradication, IM recurred in 13% (95% CI, 9%-18%). Progression to cancer occurred in 0.2% of patients during treatment and in 0.7% of those after CE-IM. Esophageal stricture was the most common adverse event and was reported in 5% of patients (95% CI, 3%-7%). Confidence in most summary estimates was limited by a high degree of heterogeneity, which did not appear to be caused by single outlier studies. Conclusions: Treatment of BE with RFA results in CE-D and CE-IM in a high proportion of patients, with few recurrences of IM after treatment and a low rate of adverse events. Despite the large amount of study heterogeneity, these data provide additional information for patients and providers to make informed treatment decisions.

Original languageEnglish (US)
Pages (from-to)1245-1255
Number of pages11
JournalClinical Gastroenterology and Hepatology
Volume11
Issue number10
DOIs
StatePublished - Oct 2013
Externally publishedYes

Fingerprint

Barrett Esophagus
Meta-Analysis
Metaplasia
Confidence Intervals
Cohort Studies
Therapeutics
Recurrence
Esophageal Stenosis
PubMed
Retrospective Studies
Prospective Studies

Keywords

  • Endoscopy
  • Esophageal Cancer
  • Gastroesophageal Reflux
  • Prevention

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Efficacy and durability of radiofrequency ablation for barrett's esophagus : Systematic review and meta-analysis. / Orman, Eric; Li, Nan; Shaheen, Nicholas J.

In: Clinical Gastroenterology and Hepatology, Vol. 11, No. 10, 10.2013, p. 1245-1255.

Research output: Contribution to journalReview article

@article{596d37343f0e4834b22a3d048a5e2445,
title = "Efficacy and durability of radiofrequency ablation for barrett's esophagus: Systematic review and meta-analysis",
abstract = "Background & Aims: In patients with Barrett's esophagus (BE), radiofrequency ablation (RFA) safely and effectively eradicates dysplasia and intestinal metaplasia. We aimed to determine the efficacy and durability of RFA for patients with dysplastic and nondysplastic BE. Methods: We performed a systematic review and meta-analysis of studies identified in PubMed and EMBASE that reported the proportion of patients treated with RFA who had complete eradication of dysplasia (CE-D) and intestinal metaplasia (CE-IM), and the proportion of patients with recurrent IM after successful treatment. Pooled estimates of CE-D, CE-IM, IM recurrence, and adverse events were calculated. Results: We identified 18 studies of 3802 patients reporting efficacy and 6 studies of 540 patients reporting durability. Ten were prospective cohort studies, 9 were retrospective cohort studies, and 1 was a randomized trial. CE-IM was achieved in 78{\%} of patients (95{\%} confidence interval [CI], 70{\%}-86{\%}) and CE-D was achieved in 91{\%} (95{\%} CI, 87{\%}-95{\%}). After eradication, IM recurred in 13{\%} (95{\%} CI, 9{\%}-18{\%}). Progression to cancer occurred in 0.2{\%} of patients during treatment and in 0.7{\%} of those after CE-IM. Esophageal stricture was the most common adverse event and was reported in 5{\%} of patients (95{\%} CI, 3{\%}-7{\%}). Confidence in most summary estimates was limited by a high degree of heterogeneity, which did not appear to be caused by single outlier studies. Conclusions: Treatment of BE with RFA results in CE-D and CE-IM in a high proportion of patients, with few recurrences of IM after treatment and a low rate of adverse events. Despite the large amount of study heterogeneity, these data provide additional information for patients and providers to make informed treatment decisions.",
keywords = "Endoscopy, Esophageal Cancer, Gastroesophageal Reflux, Prevention",
author = "Eric Orman and Nan Li and Shaheen, {Nicholas J.}",
year = "2013",
month = "10",
doi = "10.1016/j.cgh.2013.03.039",
language = "English (US)",
volume = "11",
pages = "1245--1255",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "10",

}

TY - JOUR

T1 - Efficacy and durability of radiofrequency ablation for barrett's esophagus

T2 - Systematic review and meta-analysis

AU - Orman, Eric

AU - Li, Nan

AU - Shaheen, Nicholas J.

PY - 2013/10

Y1 - 2013/10

N2 - Background & Aims: In patients with Barrett's esophagus (BE), radiofrequency ablation (RFA) safely and effectively eradicates dysplasia and intestinal metaplasia. We aimed to determine the efficacy and durability of RFA for patients with dysplastic and nondysplastic BE. Methods: We performed a systematic review and meta-analysis of studies identified in PubMed and EMBASE that reported the proportion of patients treated with RFA who had complete eradication of dysplasia (CE-D) and intestinal metaplasia (CE-IM), and the proportion of patients with recurrent IM after successful treatment. Pooled estimates of CE-D, CE-IM, IM recurrence, and adverse events were calculated. Results: We identified 18 studies of 3802 patients reporting efficacy and 6 studies of 540 patients reporting durability. Ten were prospective cohort studies, 9 were retrospective cohort studies, and 1 was a randomized trial. CE-IM was achieved in 78% of patients (95% confidence interval [CI], 70%-86%) and CE-D was achieved in 91% (95% CI, 87%-95%). After eradication, IM recurred in 13% (95% CI, 9%-18%). Progression to cancer occurred in 0.2% of patients during treatment and in 0.7% of those after CE-IM. Esophageal stricture was the most common adverse event and was reported in 5% of patients (95% CI, 3%-7%). Confidence in most summary estimates was limited by a high degree of heterogeneity, which did not appear to be caused by single outlier studies. Conclusions: Treatment of BE with RFA results in CE-D and CE-IM in a high proportion of patients, with few recurrences of IM after treatment and a low rate of adverse events. Despite the large amount of study heterogeneity, these data provide additional information for patients and providers to make informed treatment decisions.

AB - Background & Aims: In patients with Barrett's esophagus (BE), radiofrequency ablation (RFA) safely and effectively eradicates dysplasia and intestinal metaplasia. We aimed to determine the efficacy and durability of RFA for patients with dysplastic and nondysplastic BE. Methods: We performed a systematic review and meta-analysis of studies identified in PubMed and EMBASE that reported the proportion of patients treated with RFA who had complete eradication of dysplasia (CE-D) and intestinal metaplasia (CE-IM), and the proportion of patients with recurrent IM after successful treatment. Pooled estimates of CE-D, CE-IM, IM recurrence, and adverse events were calculated. Results: We identified 18 studies of 3802 patients reporting efficacy and 6 studies of 540 patients reporting durability. Ten were prospective cohort studies, 9 were retrospective cohort studies, and 1 was a randomized trial. CE-IM was achieved in 78% of patients (95% confidence interval [CI], 70%-86%) and CE-D was achieved in 91% (95% CI, 87%-95%). After eradication, IM recurred in 13% (95% CI, 9%-18%). Progression to cancer occurred in 0.2% of patients during treatment and in 0.7% of those after CE-IM. Esophageal stricture was the most common adverse event and was reported in 5% of patients (95% CI, 3%-7%). Confidence in most summary estimates was limited by a high degree of heterogeneity, which did not appear to be caused by single outlier studies. Conclusions: Treatment of BE with RFA results in CE-D and CE-IM in a high proportion of patients, with few recurrences of IM after treatment and a low rate of adverse events. Despite the large amount of study heterogeneity, these data provide additional information for patients and providers to make informed treatment decisions.

KW - Endoscopy

KW - Esophageal Cancer

KW - Gastroesophageal Reflux

KW - Prevention

UR - http://www.scopus.com/inward/record.url?scp=84884357436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884357436&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2013.03.039

DO - 10.1016/j.cgh.2013.03.039

M3 - Review article

VL - 11

SP - 1245

EP - 1255

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 10

ER -